[Explanation] Recently, the "Respiratory Virus (6 Kinds) Nucleic Acid Detection Kit (Isothermal Amplification Chip Method)" jointly designed and developed by West China Hospital of Sichuan University, Chengdu Boao Jingxin Biotechnology Co., Ltd. and Tsinghua University has been awarded China National Drug The second batch of new coronavirus emergency medical devices was approved by the Supervision and Administration. Just take a patient's nasopharyngeal swab and other secretion samples, and one-time detection of six common respiratory viruses, including neocrown virus, can be performed within 1.5 hours.

On February 24, the reporter visited the production workshop of Chengdu Boao Jingxin Biotechnology Co., Ltd. in Wenjiang, Chengdu, for a site visit. At the production site of six respiratory virus nucleic acid detection kits, the reporter saw that the staff was printing.

[Same period] (Reagent Workshop Director Xie Wanrong) Our current procedure is to place one of our chips on our spotting tray, and then on one of our spotting instruments, and use our spotting instrument to place us in various positions. The spotting solution is placed on our chip, which is a printing process.

[Explanation] According to reports, this is the country's first multi-targeted new crown virus nucleic acid detection kit. New crown virus nucleic acid testing products that have been approved for clinical use are all RT-RCR detection reagents for a single indicator of COVID-19. They can only distinguish between normal people and patients with new crown pneumonia virus infection, and cannot achieve the purpose of effective investigation. The test product has the characteristics of "faster, more, and more secure": high sample throughput, only 1.5 hours for one test, can test more samples at the same time (each device can test 16 samples at the same time); Multi-indicator (6 items) joint inspection is convenient for clinical differential diagnosis and decision-making, shunts common influenza and new crown virus infection, and reduces the risk and burden of doctors and patients.

[Contemporary] (Song Yunpeng, General Manager of Chengdu Boao Jingxin Biotechnology Co., Ltd.) The current production situation is that we can produce 24,000 test chip reagents per day, and then our output is 500 units per month. More than a dozen instruments were urgently transferred to Hubei. They were just shipped off last night. They should arrive at Hubei Huoshenshan Hospital tomorrow morning. Before, that is, before being tried, they also put one in Huoshenshan Hospital for trial. , And then the effect is very good, so we immediately assemble a wholesale to Hubei.

[Explanation] It is understood that the Chengdu Medical City, located in Wenjiang, Chengdu, fully supports epidemic prevention projects, establishes precise assistance mechanisms for scientific and technological research carried out by technology companies and universities, and develops protective supplies, disinfection products, drug development, Enterprises and colleges and universities that research and develop new technologies and new products such as testing reagents and equipment, emergency equipment, and new products will grant a subsidy of up to 2 million yuan based on 10% of the actual R & D investment.

[Contemporary] (Secretary of the Party Working Committee of Chengdu Medical City Zhou Shigang) Chengdu Medical City is the main position for the development of the health industry in Chengdu, Sichuan Province. We give full play to the advantages of the integration of the three doctors. Production enterprises are quick to carry out R & D and production, relying on the professional advantages of the park, and strive to find breakthroughs. At present, Boao has achieved initial results and achieved mass production.

Reporter He Zheng reports from Chengdu

Editor-in-chief: [Wang Kai]